PL1994152T3 - Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek - Google Patents

Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek

Info

Publication number
PL1994152T3
PL1994152T3 PL07710660T PL07710660T PL1994152T3 PL 1994152 T3 PL1994152 T3 PL 1994152T3 PL 07710660 T PL07710660 T PL 07710660T PL 07710660 T PL07710660 T PL 07710660T PL 1994152 T3 PL1994152 T3 PL 1994152T3
Authority
PL
Poland
Prior art keywords
tumors
destruction
cells
removal
treatment
Prior art date
Application number
PL07710660T
Other languages
English (en)
Inventor
Jack Gemmell
Paul A Averback
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of PL1994152T3 publication Critical patent/PL1994152T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
PL07710660T 2006-02-28 2007-02-28 Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek PL1994152T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77693306P 2006-02-28 2006-02-28
EP07710660A EP1994152B1 (en) 2006-02-28 2007-02-28 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
PCT/CA2007/000318 WO2007098588A1 (en) 2006-02-28 2007-02-28 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Publications (1)

Publication Number Publication Date
PL1994152T3 true PL1994152T3 (pl) 2013-05-31

Family

ID=38458614

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07710660T PL1994152T3 (pl) 2006-02-28 2007-02-28 Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek

Country Status (17)

Country Link
US (2) US8067378B2 (pl)
EP (1) EP1994152B1 (pl)
JP (1) JP2009528298A (pl)
KR (1) KR20080110765A (pl)
CN (1) CN101389760A (pl)
AU (1) AU2007219669A1 (pl)
BR (1) BRPI0708340A2 (pl)
CA (1) CA2643100A1 (pl)
DK (1) DK1994152T3 (pl)
EA (1) EA200801853A1 (pl)
ES (1) ES2400920T3 (pl)
MX (1) MX2008010942A (pl)
PL (1) PL1994152T3 (pl)
PT (1) PT1994152E (pl)
SI (1) SI1994152T1 (pl)
WO (1) WO2007098588A1 (pl)
ZA (1) ZA200807394B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0708340A2 (pt) * 2006-02-28 2011-05-24 Nymox Corp peptìdio isolado, mimético dele, composição, processo de tratamento de uma condição em um mamìfero requerendo remoção ou destruição de células, e processo de prevenção ou inibição de estenose, oclusão ou bloqueio de um cateter
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP3191131A4 (en) 2014-08-21 2018-09-05 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) * 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) * 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752602A (en) * 1985-09-09 1988-06-21 Board Of Regents, The University Of Texas System Dipeptide alkyl esters and their uses
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
ES2255054T3 (es) * 1993-04-20 2006-06-16 The General Hospital Corporation Expresion del gen de la proteina neurofilamentosa y deteccion de la enfermedad de alzheimer.
CU22921A1 (es) * 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
ATE335765T1 (de) * 2000-05-24 2006-09-15 Hoffmann La Roche Antikörper gegen spezielle formen des propsa und deren verwendung in immunoassays
EP1541166B1 (en) * 2001-05-16 2007-12-19 Nymox Corporation Preventing cell death using segments of neural thread proteins
MXPA04000561A (es) 2001-07-19 2005-02-17 Nymox Corp Peptidos eficaces en el tratamiento de tumores y otras condiciones que requieren la remocion o destruccion de celulas.
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
BRPI0708340A2 (pt) * 2006-02-28 2011-05-24 Nymox Corp peptìdio isolado, mimético dele, composição, processo de tratamento de uma condição em um mamìfero requerendo remoção ou destruição de células, e processo de prevenção ou inibição de estenose, oclusão ou bloqueio de um cateter

Also Published As

Publication number Publication date
BRPI0708340A2 (pt) 2011-05-24
PT1994152E (pt) 2013-03-13
CA2643100A1 (en) 2007-09-07
US8716247B2 (en) 2014-05-06
WO2007098588A1 (en) 2007-09-07
CN101389760A (zh) 2009-03-18
EA200801853A1 (ru) 2009-02-27
AU2007219669A1 (en) 2007-09-07
EP1994152A4 (en) 2009-04-01
SI1994152T1 (sl) 2013-05-31
EP1994152B1 (en) 2012-12-12
EP1994152A1 (en) 2008-11-26
KR20080110765A (ko) 2008-12-19
JP2009528298A (ja) 2009-08-06
US8067378B2 (en) 2011-11-29
MX2008010942A (es) 2008-09-03
ZA200807394B (en) 2009-08-26
ES2400920T3 (es) 2013-04-15
DK1994152T3 (da) 2013-03-11
US20120114679A1 (en) 2012-05-10
US20080176805A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
ZA200807394B (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
IL261346A (en) Tissue protective peptides and their uses
ZA200800464B (en) Peptides for use in the treatment of obesity
ZA200803048B (en) Microangiopathy treatment and prevention
IL186447A0 (en) Methods for the treatment of substance abuse and dependence
IL184356A0 (en) Indoles useful in the treatment of inflammation
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
GB2429013C (en) Peptides for treatment and diagnosis of autoimmunedisease
IL210810B (en) Peptides to treat pain and/or inflammation
IL204566A0 (en) Adherent cells from adipose or placeta tissues and use thereof in therapy
GB0602357D0 (en) Authentication of cheques and the like
EP1877344A4 (en) BIOFILTER UNITS AND WATER TREATMENT PLANTS THEREWITH
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
IL186325A0 (en) Tizanidine compositions and methods of treatment using the compositions
IL192372A0 (en) Inhibition of cxcr4 and/or cell motility
IL198721A0 (en) Acat inhibitors and their use in the prevention or treatment of fibrosis
IL188404A0 (en) Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
ZA200709443B (en) Methods for the treatment of substance abuse and dependence
ZA201000483B (en) Substances for the protection of cells and/or tissues
IL195888A0 (en) Materials handling and treatment
EP1956001A4 (en) PHARMACEUTICAL PRODUCT FOR USE IN THE TREATMENT OF URETEROLITHIASE
HK1119954A (en) Use of neboglamine in the treatment of toxicodependency
IL229577A (en) Amino-sugars and their use to treat genetic diseases
PL381819A1 (pl) Sposób oczyszczania i wykorzystania gliceryny odpadowej